FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288096714> ?p ?o ?g. }

• W4288096714 abstract "Based on studies implicating the type 2 cytokine interleukin 13 (IL-13) as a potential contributor to critical coronavirus disease 2019 (COVID-19), this trial was designed as an early phase 2 study to assess dupilumab, a monoclonal antibody that blocks IL-13 and interleukin 4 signaling, for treatment of inpatients with COVID-19.We conducted a phase 2a randomized, double-blind, placebo-controlled trial (NCT04920916) to assess the safety and efficacy of dupilumab plus standard of care vs placebo plus standard of care in mitigating respiratory failure and death in those hospitalized with COVID-19.Forty eligible subjects were enrolled from June to November of 2021. There was no statistically significant difference in adverse events nor in the primary endpoint of ventilator-free survival at day 28 between study arms. However, for the secondary endpoint of mortality at day 60, there were 2 deaths in the dupilumab group compared with 5 deaths in the placebo group (60-day survival: 89.5% vs 76.2%; adjusted hazard ratio [HR], 0.05 [95% confidence interval {CI}, .004-.72]; P = .03). Among subjects who were not in the intensive care unit (ICU) at randomization, 3 subjects in the dupilumab arm were admitted to the ICU compared to 6 in the placebo arm (17.7% vs 37.5%; adjusted HR, 0.44 [95% CI, .09-2.09]; P = .30). Last, we found evidence of type 2 signaling blockade in the dupilumab group through analysis of immune biomarkers over time.Although the primary outcome of day 28 ventilator-free survival was not reached, adverse events were not observed and survival was higher in the dupilumab group by day 60.NCT04920916." @default.
• W4288096714 created "2022-07-28" @default.
• W4288096714 creator A5002913856 @default.
• W4288096714 creator A5008679993 @default.
• W4288096714 creator A5010613527 @default.
• W4288096714 creator A5028001292 @default.
• W4288096714 creator A5035083346 @default.
• W4288096714 creator A5045368960 @default.
• W4288096714 creator A5050404191 @default.
• W4288096714 creator A5057736862 @default.
• W4288096714 creator A5067812622 @default.
• W4288096714 creator A5071055903 @default.
• W4288096714 creator A5072513067 @default.
• W4288096714 creator A5073921269 @default.
• W4288096714 creator A5090894597 @default.
• W4288096714 date "2022-07-27" @default.
• W4288096714 modified "2023-10-15" @default.
• W4288096714 title "Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial" @default.
• W4288096714 cites W2046208657 @default.
• W4288096714 cites W2168938667 @default.
• W4288096714 cites W2342693354 @default.
• W4288096714 cites W2610814011 @default.
• W4288096714 cites W2805002966 @default.
• W4288096714 cites W2917101705 @default.
• W4288096714 cites W3027630905 @default.
• W4288096714 cites W3043831218 @default.
• W4288096714 cites W3047144258 @default.
• W4288096714 cites W3096383810 @default.
• W4288096714 cites W3113196149 @default.
• W4288096714 cites W3126819714 @default.
• W4288096714 cites W3129869280 @default.
• W4288096714 cites W3130126061 @default.
• W4288096714 cites W3135176010 @default.
• W4288096714 cites W3136148042 @default.
• W4288096714 cites W3158758896 @default.
• W4288096714 cites W3163366978 @default.
• W4288096714 cites W3163989045 @default.
• W4288096714 cites W3173905692 @default.
• W4288096714 cites W3202803280 @default.
• W4288096714 cites W3211002229 @default.
• W4288096714 cites W3215603779 @default.
• W4288096714 cites W4200181573 @default.
• W4288096714 cites W4200468953 @default.
• W4288096714 cites W4205760778 @default.
• W4288096714 cites W4210642183 @default.
• W4288096714 cites W4220670893 @default.
• W4288096714 cites W4226280844 @default.
• W4288096714 doi "https://doi.org/10.1093/ofid/ofac343" @default.
• W4288096714 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35959207" @default.
• W4288096714 hasPublicationYear "2022" @default.
• W4288096714 type Work @default.
• W4288096714 citedByCount "13" @default.
• W4288096714 countsByYear W42880967142022 @default.
• W4288096714 countsByYear W42880967142023 @default.
• W4288096714 crossrefType "journal-article" @default.
• W4288096714 hasAuthorship W4288096714A5002913856 @default.
• W4288096714 hasAuthorship W4288096714A5008679993 @default.
• W4288096714 hasAuthorship W4288096714A5010613527 @default.
• W4288096714 hasAuthorship W4288096714A5028001292 @default.
• W4288096714 hasAuthorship W4288096714A5035083346 @default.
• W4288096714 hasAuthorship W4288096714A5045368960 @default.
• W4288096714 hasAuthorship W4288096714A5050404191 @default.
• W4288096714 hasAuthorship W4288096714A5057736862 @default.
• W4288096714 hasAuthorship W4288096714A5067812622 @default.
• W4288096714 hasAuthorship W4288096714A5071055903 @default.
• W4288096714 hasAuthorship W4288096714A5072513067 @default.
• W4288096714 hasAuthorship W4288096714A5073921269 @default.
• W4288096714 hasAuthorship W4288096714A5090894597 @default.
• W4288096714 hasBestOaLocation W42880967141 @default.
• W4288096714 hasConcept C126322002 @default.
• W4288096714 hasConcept C142724271 @default.
• W4288096714 hasConcept C168563851 @default.
• W4288096714 hasConcept C197934379 @default.
• W4288096714 hasConcept C203092338 @default.
• W4288096714 hasConcept C204243189 @default.
• W4288096714 hasConcept C204787440 @default.
• W4288096714 hasConcept C207103383 @default.
• W4288096714 hasConcept C27081682 @default.
• W4288096714 hasConcept C2776042228 @default.
• W4288096714 hasConcept C2776376669 @default.
• W4288096714 hasConcept C2777014857 @default.
• W4288096714 hasConcept C2779824493 @default.
• W4288096714 hasConcept C44249647 @default.
• W4288096714 hasConcept C71924100 @default.
• W4288096714 hasConceptScore W4288096714C126322002 @default.
• W4288096714 hasConceptScore W4288096714C142724271 @default.
• W4288096714 hasConceptScore W4288096714C168563851 @default.
• W4288096714 hasConceptScore W4288096714C197934379 @default.
• W4288096714 hasConceptScore W4288096714C203092338 @default.
• W4288096714 hasConceptScore W4288096714C204243189 @default.
• W4288096714 hasConceptScore W4288096714C204787440 @default.
• W4288096714 hasConceptScore W4288096714C207103383 @default.
• W4288096714 hasConceptScore W4288096714C27081682 @default.
• W4288096714 hasConceptScore W4288096714C2776042228 @default.
• W4288096714 hasConceptScore W4288096714C2776376669 @default.
• W4288096714 hasConceptScore W4288096714C2777014857 @default.
• W4288096714 hasConceptScore W4288096714C2779824493 @default.
• W4288096714 hasConceptScore W4288096714C44249647 @default.
• W4288096714 hasConceptScore W4288096714C71924100 @default.
• W4288096714 hasFunder F4320312430 @default.

• next